Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Tellgen

Tellgen?uq=kzBhZRuG
2003 FOUNDED
PUBLIC STATUS
301-400 EMPLOYEES
300642 STOCK SYMBOL
$6.93 SHARE PRICE (As of Monday Closing)
Description

Developer of vitro diagnostic reagents intended to treat tumor, infectious and reproductive diseases. The company is focused in development and manufacturing of tumor markers screening and gene mutation detection technology for clinical diagnosis, research use and health centers.

Website
Formerly Known As
Through King Life Technology
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Stock Exchange
SHE
Primary Office
  • Building 1, No.115, Lane 572
  • Bibo Road, Free Trade Zone
  • Shanghai, Pudong 201203
  • China

+86 021 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Tellgen’s full profile, request a free trial.

Tellgen Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$6.61 - $11.79 $639M $7.04 $0.23 895K 90.8M

Tellgen Financials Summary

In Thousands,
USD
TTM
31-Mar-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2013
31-Dec-2013
Enterprise Value 946,422 749,612
Revenue 47,170 44,820 34,713 12,493
EBITDA 22,228 24,330 19,606 5,138
Net Income 19,180 18,765 14,678 3,671
Total Assets 155,277 143,239 49,041 21,109
Total Debt 0 2,214 2,365
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tellgen Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Tellgen‘s full profile, request access.

Request full access to PitchBook

Tellgen Executive Team (1)

Name Title Board
Seat
Contact
Info
Jianer Yao Chief Executive Officer